A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis

Arthritis and Rheumatology

Volumn 67, Issue 11, 2015, Pages 3004-3016

  Rice, Lisa M ^a   Ziemek, Jessica ^a   Stratton, Eric A ^a   McLaughlin, Sarah R ^a   Padilla, Cristina M ^a   Mathes, Allison L ^a   Christmann, Romy B ^a   Stifano, Giuseppina ^a   Browning, Jeffrey L ^a   Whitfield, Michael L ^b   Spiera, Robert F ^c   Gordon, Jessica K ^c   Simms, Robert W ^a   Zhang, Yuqing ^a   Lafyatis, Robert ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE PROTEIN; MEMBRANE PROTEIN 1; MEMBRANE PROTEIN 2; MEMBRANE PROTEIN 3; MS4A4A PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PROTEASOME ACTIVATOR SUBUNIT 2 BETA; PROTEIN; PROTEIN P35; PSMD10 PROTEIN; PSMD9 PROTEIN; SCRAMBLASE; SECRETED FRIZZLED RELATED PROTEIN 4; SIALOADHESIN; SOMATOMEDIN BINDING PROTEIN 3; STAT1 PROTEIN; TAPASIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT2 PROTEIN; ANTIGEN; CYTOSKELETON PROTEIN; IFI44 PROTEIN, HUMAN; SIGLEC1 PROTEIN, HUMAN;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; GENE CLUSTER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROARRAY ANALYSIS; OVERLAPPING GENE; PHARMACODYNAMIC PARAMETERS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SKIN BIOPSY; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; UPREGULATION; DIFFUSE SCLERODERMA; GENETICS; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SKIN; THEORETICAL MODEL;

ANTIGENS; BIOMARKERS; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CYTOSKELETAL PROTEINS; GENE EXPRESSION; HUMANS; MODELS, THEORETICAL; SCLERODERMA, DIFFUSE; SEVERITY OF ILLNESS INDEX; SIALIC ACID BINDING IG-LIKE LECTIN 1; SKIN; THROMBOSPONDIN 1;

EID: 84946024731     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39287     Document Type: Article

References (28)

1. Farina G, Lafyatis D, Lemaire R, Lafyatis R., A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010; 62: 580-8.
2. Gordon JK, Magro C, Udeh U, Lerner D, Wildman HF, Huang WT, et al., Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: a single group, open label pilot clinical trial: one year results [abstract]. Arthritis Rheum 2013: 65: S30-2.
3. De Hoon MJ, Imoto S, Nolan J, Miyano S., Open source clustering software. Bioinformatics 2004; 20: 1453-4.
4. Saldanha AJ., Java Treeview: extensible visualization of microarray data. Bioinformatics 2004; 20: 3246-8.
5. Kissin EY, Merkel PA, Lafyatis R., Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 2006; 54: 3655-60.
6. Mathes AL, Christmann RB, Stifano G, Affandi AJ, Radstake TR, Farina GA, et al., Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin. Ann Rheum Dis 2014; 73: 1864-72.
7. Friendly M., Corrgrams: exploratory displays for correlation matrices. Am Stat 2002; 56: 316-24.
8. Wright K., Corrgram: plot a correlogram. R package version 1.6. 2014. URL: http://CRAN.R-project.org/package=corrgram.
9. McGraw KO, Wong SP., Forming inferences about some intraclass correlation coefficients. Psychol Methods 1996; 1: 30-46.
10. Zhang Y, Zhang B, Wise B, Niu J, Zhu Y., Statistical approaches to evaluating the effect of risk factors on the pain of knee osteoarthritis in longitudinal studies. Curr Opin Rheumatol 2009; 21: 513-9.
11. Bayle J, Fitch J, Jacobsen K, Kumar R, Lafyatis R, Lemaire R., Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol 2008; 128: 871-81.
12. Greenblatt MB, Sargent JL, Farina G, Tsang K, Lafyatis R, Glimcher LH, et al., Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol 2012; 180: 1080-94.
13. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, et al., Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995; 105: 280-4.
14. Kikuchi K, Kadono T, Ihn H, Sato S, Igarashi A, Nakagawa H, et al., Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-β1. J Invest Dermatol 1995; 105: 128-32.
15. Gerstmeier H, Gabrielli A, Meurer M, Brocks D, Braun-Falco O, Krieg T., Levels of type IV collagen and laminin fragments in serum from patients with progressive systemic sclerosis. J Rheumatol 1988; 15: 969-72.
16. Brissett M, Veraldi KL, Pilewski JM, Medsger TA Jr, Feghali-Bostwick CA., Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3. Arthritis Rheum 2012; 64: 272-80.
17. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, et al., Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010; 16: 1009-17.
18. Strehl B, Seifert U, Kruger E, Heink S, Kuckelkorn U, Kloetzel PM., Interferon-γ, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 2005; 207: 19-30.
19. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schroter F, et al., Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 2010; 142: 613-24.
20. Nandi D, Woodward E, Ginsburg DB, Monaco JJ., Intermediates in the formation of mouse 20S proteasomes: implications for the assembly of precursor β subunits. EMBO J 1997; 16: 5363-75.
21. Abarca-Heidemann K, Friederichs S, Klamp T, Boehm U, Guethlein LA, Ortmann B., Regulation of the expression of mouse TAP-associated glycoprotein (tapasin) by cytokines. Immunol Lett 2002; 83: 197-207.
22. Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML, et al., Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PloS One 2010; 5: e12106.
23. Kahaleh MB, Osborn I, LeRoy EC., Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981; 94: 482-4.
24. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al., Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3958-67.
25. Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, et al., Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 2015; 125: 2795-807.
26. Stifano G, Affandi AJ, Mathes AL, Rice LM, Nakerakanti S, Nazari B, et al., Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor β signature gene expression, and fibrosis. Arthritis Res Ther 2014; 16: R136.
27. Montoro-Garcia S, Shantsila E, Lip GY., Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease. Expert Opin Ther Targets 2014; 18: 43-53.
28. Wiseman S, Marlborough F, Doubal F, Webb DJ, Wardlaw J., Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: systematic review and meta-analysis. Cerebrovasc Dis 2014; 37: 64-75.